<DOC>
	<DOC>NCT01963715</DOC>
	<brief_summary>This is a Phase 1, first-in-human study to determine the recommended dose of IMGN289 in adult patients with advanced EGFR-positive tumors.</brief_summary>
	<brief_title>A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<criteria>18 years old at time of consent Diagnosed with a solid tumor that has progressed despite standard therapy or for which no standard effective or curative options exist or are suitable EGFRpositive tumor expression Adequate blood and organ function Must agree to use contraception while on study and for 12 weeks after the last dose of IMGN289 as applicable Must be willing and able to sign informed consent and follow the study schedule and other protocol requirements Other anticancer treatment during the study Symptomatic brain metastases Other clinically significant disease as defined by the protocol Chronic skin condition that requires prescribed oral or intravenous treatment History of severe rash that required discontinuation of prior EGFR targeted therapy Receiving therapeutic doses of warfarin or heparin for anticoagulation Known diagnosis of HIV or active viral hepatitis Women who are pregnant or breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>IMGN289</keyword>
	<keyword>Antibody Drug Conjugate</keyword>
	<keyword>antibody</keyword>
	<keyword>EGFR</keyword>
	<keyword>NSCLC</keyword>
	<keyword>SCCHN</keyword>
	<keyword>Head and neck</keyword>
	<keyword>Squamous cell carcinoma</keyword>
	<keyword>Solid tumor</keyword>
	<keyword>Immunogen</keyword>
	<keyword>Lung</keyword>
	<keyword>Phase 1</keyword>
</DOC>